Search

Your search keyword '"Giralt, Sergio"' showing total 4,919 results

Search Constraints

Start Over You searched for: Author "Giralt, Sergio" Remove constraint Author: "Giralt, Sergio"
4,919 results on '"Giralt, Sergio"'

Search Results

1. Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma

2. Comparison of infectious complications with BCMA-directed therapies in multiple myeloma

3. Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma

4. Phase I Trial of MCARH109, a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis

6. Altered microbial bile acid metabolism exacerbates T cell-driven inflammation during graft-versus-host disease

7. Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies

8. Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective Cohort

9. Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets.

10. Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

11. Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens

12. Artificial intelligence enabled interpretation of ECG images to predict hematopoietic cell transplantation toxicity

14. Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma

16. Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy

17. Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies

18. Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)

19. CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma

20. A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia

21. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial

23. Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing

24. Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma

25. Phase 2 trial of cyclosporine-A, mycophenolate mofetil, and tocilizumab GVHD prophylaxis in cord blood transplantation

26. Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

30. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study.

32. Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation

33. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents.

34. Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes

35. Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma

36. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis

37. Analysis of disparities in time to allogeneic transplantation in adults with acute myelogenous leukemia

38. High-resolution analyses of associations between medications, microbiome, and mortality in cancer patients

41. A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract

42. Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort study

44. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy

45. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

46. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial

49. Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplant

Catalog

Books, media, physical & digital resources